PDGFR

Inhibitory Selectivity
Catalog No.Inhibitor Name PDGFRPDGFRαPDGFRβOther
A10001Sorafenib Tosylate
**
**
Raf-1,VEGFR2/Flk1,B-Raf
A10468Imatinib Mesylate
c-Kit,v-Abl
A10880Sunitinib Malate
****
FLT3,Kit,VEGFR2
A10080Ponatinib
****
Abl,VEGFR2,FGFR1
A10103Axitinib
***
****
VEGFR1/FLT1,VEGFR2/Flk1,VEGFR3
A10259Imatinib
**
c-Kit,v-Abl
A10137Nintedanib
**
**
VEGFR3,VEGFR2,LCK
A10699Pazopanib HCl
**
VEGFR1,VEGFR2,VEGFR3
A11411Dovitinib
*
***
FLT3,c-Kit,FGFR1
A10025Linifanib
**
VEGFR1/FLT1,CSF-1R,FLT3
A11052Crenolanib
****
****
A10558Masitinib
*
*
Kit,Lyn B,Abl1
A10101Tivozanib
***
**
VEGFR2,VEGFR3,EphB2
A10610Amuvatinib
***
c-Kit (D816H),FLT3 (D835Y)
A10608Motesanib Diphosphate
**
VEGFR1,VEGFR2,VEGFR3
A10953Orantinib
***
FGFR1,Flk1
A11350CP-673451
***
****
c-Kit,VEGFR2,VEGFR1
A10502Ki8751
**
VEGFR2,c-Kit,FGFR2
A10903Telatinib
***
c-Kit,VEGFR3,VEGFR2
A11207PP121
****
Hck,VEGFR,mTOR
A11518Pazopanib
**
VEGFR1,VEGFR2,VEGFR3
A10504KRN 633
*
*
VEGFR3,VEGFR2,VEGFR1
A10198Dovitinib Dilactic Acid
*
***
FLT3,c-Kit,VEGFR3/FLT4
A11753MK-2461
***
c-Met (M1250T),c-Met (Y1235D),c-Met (Y1230H)
A14156AZD2932
****
Flt3,VEGFR-2,c-Kit
A15062DCC-2618
***
***
c-Kit

Notes:
1.Hover mouse over " * " to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of " * " is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.



40 Item(s)

per page

Set Descending Direction
Catalog No. Product Name Application Product Information
A16246

AC710 Mesylate

FLT3/KIT/PDGFRα/PDGFRβ inhibitor
AC710 Mesylate is a potent, selective PDGFR-family kinases inhibitor with Kd values of 0.6 nM/1.0 nM/1.3 nM/1.0 nM for FLT3/KIT/PDGFRα/PDGFRβ respectively.
A13530

Flumatinib mesylate

c-Abl/c-Kit/PDGRFβ inhibitor
Flumatinib mesylate can reduce the expression of C-MYC, HIF-1 a and VEGF in U266 cell line in a time- and dose-dependent manners, so flumatinib mesylate may become a new drug for MM therapy.
A11472 SALE

Ki 20227

M-CSFR, CSF1R inhibitor
Ki 20227 is an inhibitor of c-Fms tyrosine kinase (M-CSFR, CSF1R).
A13111 SALE

R1530

Chk2, KDR, FGFR, Aurora A & Cdk2 inhibitor
R1530 is a pyrazolobenzodiazepine small molecule with potential antiangiogenesis and antineoplastic activities. R1530 is also a mitosis-angiogenesis inhibitor (MAI) that inhibits multiple receptor tyrosine kinases involved in angiogenesis, such as vascular endothelial growth factor receptor (VEGFR)-1, -2, -3, platelet-derived growth factor receptor (PDGFR) beta? FMS-like tyrosine kinase (Flt)-3, and fibroblast growth factor receptor (FGFR) -1, -2.
A11581 SALE

Toceranib (PHA 291639, SU 11654)

c-Kit, PDGFR, VEGFR inhibitor
Toceranib is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRβ.
A11350 SALE

CP-673451

PDGFRα/β inhibitor
CP 673451 is a potent PDGFR-β inhibitor with an IC50 of 1 nM.
A11518 SALE

Pazopanib (GW-786034)

VEGFR inhibitor
Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit that blocks tumor growth and inhibits angiogenesis.
A11753

MK-2461

c-Met Inhibitor
MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
A10504

KRN 633

VEGFR Inhibitor
KRN 633 is a cell-permeable, reversible, ATP-competitive VEGFR kinase inhibitor that inhibits PDGFR-α and c-Kit at higher concentrations only (IC50 = 0.97 μM and 4.33 μM, respectively) and inactive towards 17 other kinases (IC50 ≥ 10 μM).
A14156

AZD 2932

mutil-targeted protein tyrosine kinase inhibitor
AZD2932 is a potent and mutil-targeted protein tyrosine kinase inhibitor with IC50 of 8 nM, 4 nM, 7 nM, and 9 nM for VEGFR-2, PDGFRβ, Flt-3, and c-Kit, respectively.
A13545

JI-101

VEGFR2/PDGFRβ/EphB4 inhibitor
JI-101 is an orally active inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor beta (PDGFRβ), and the ephrin B4 receptor B4 (EphB4) with potential antiangiogenic and antineoplastic activities.
A16197

Nintedanib esylate

RTK inhibitor
Nintedanib is a potent inhibitor of multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs).
A15933

AC710

FLT3/KIT/PDGFRα/PDGFRβ inhibitor
AC710 is a potent, orally active, and selective platelet-derived growth factor receptor-family kinase inhibitor with potential anticancer activity.
A15263

Toceranib phosphate

-
Toceranib phosphate is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRβ.
A15218

Regorafenib monohydrate

Tyrosine kinase inhibitor
Regorafenib is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively.
A15182

N-Desethyl Sunitinib

VEGFR/PDGFRβ/KIT inhibitor
N-desethyl sunitinib is a major and pharmacologically active metabolite of sunitinib, which is potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor (Ki values are 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT respectively).
A15152

Masitinib mesylate

KIT/PDGFR inhibitor
Masitinib mesylate is a novel inhibitor for Kit and PDGFRα/β with IC50 of 200 nM and 540 nM/800 nM, weak inhibition to ABL and c-Fms.
A15062

DCC-2618

C-Kit/PDGFR inhibitor
DCC-2618 is a small molecule inhibitor of c-Kit and PDGFR with IC50s of 6 nM/30 nM/13 nM for c-Kit/PDGFRα/PDGFRβ respectively.
A13555

TAK-593

VEGFR/PDGFR inhibitor
TAK-593 is an oral formulation containing a small-molecule receptor tyrosine kinase inhibitor of both vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) with potential antineoplastic activity.
A10502 SALE

Ki8751

VEGFR-2 inhibitor
Ki8751 is a cell-permeable quinolyloxyphenyl-urea compound that acts as a Flk-1 (VEGFR-2)-selective inhibitior in both cell-based and cell-free assays.
A10198 SALE

Dovitinib Dilactic acid (TKI258 Dilactic acid)

RTK inhibitor
Dovitinib is a small-molecule multitargeted receptor tyrosine kinase inhibitor, which inhibits Ba/F3 cells transformed to IL3 independence by ZNF198-FGFR1 or BCR-FGFR1 with IC50 values of 150 nM and 90 nM, respectively.
A10101 SALE

Tivozanib (AV-951)

VEGFR Inhibitor
Tivozanib (AV-951) is an oral VEGF receptor tyrosine kinase inhibitor that is designed to inhibit all three VEGF receptors.
A10610

MP470 (MP-470, Amuvatinib)

RTK inhibitor
MP470 is a c-Kit/PDGFR tyrosine kinase inhibitor.
A10080 SALE

AP24534 (Ponatinib)

BCR-ABL inhibitor
AP24534 (Ponatinib) is a potent multi-kinase and pan-BCR-ABL inhibitor.
A10558 SALE

Masitinib ( AB1010)

c-Kit inhibitor
Masitinib (AB1010) is a protein tyrosine kinase inhibitor.
A10103 SALE

Axitinib

VEGFR inhibitor
Axitinib is a small molecule tyrosine kinase inhibitor,which inhibits multiple targets, including VEGFR-1, VEGFR-2, VEGFR-3, platelet derived growth factor receptor (PDGFR), and cKIT (CD117).
A10001 SALE

Sorafenib (Nexavar)

Raf inhibitor
Sorafenib (Nexavar) is a novel, small molecular inhibitor of several tyrosine protein kinases (VEGFR and PDGFR) and RAF/MEK/ERK cascade inhibitor with an IC50 of 6, 22, 38 nM for Raf-1, wt BRAF and V599E mutant BRAF.
A10259 SALE

Imatinib (Gleevec)

PDGFR inhibitor
Imatinib (Gleevec) is a number of tyrosine kinase enzymes specific inhibitor.
A10250 SALE

Regorafenib (BAY 73-4506)

VEGFR inhibitor
Regorafenib (BAY 73-4506) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf. Regorafenib (BAY 73-4506) is an orally bioavailable multikinase inhibitor targeting both the tumor and its vasculature.
A10137 SALE

Bibf1120 (Vargatef)

VEGFR inhibitor
BIBF1120 (Vargatef) is a novel triple angiokinase inhibitor that inhibits three growth factor receptors simultaneously: VEGFR, PDGF and FGFR.
A10953 SALE

TSU-68 (Orantinib, SU6668)

PDFGRβ inhibitor
Orantinib (TSU-68, SU6668) has greatest potency against PDGFR autophosphorylation with Ki of 8 nM in a cell-free assay, but also strongly inhibits Flk-1 and FGFR1 trans-phosphorylation, little activity against IGF-1R, Met, Src, Lck, Zap70, Abl and CDK2; does not inhibit EGFR. Phase 3.
A10880 SALE

Sunitinib Malate

-
Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST).
A10699 SALE

Pazopanib HCl (GW786034)

VEGFR/PDGFR/FGFR inhibitor
Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit that blocks tumor growth and inhibits angiogenesis.
A10608

Motesanib Diphosphate (AMG-706)

VEGFR inhibitor
Motesanib, also known as AMG-706, is an orally administered multikinase inhibitor that selectively targets VEGF receptors, platelet-derived growth factor receptors, and Kit receptors.
A11207 SALE

PP121

PI3K Inhibitor
PP121 is a dual inhibitor of receptor tyrosine kinases (RTKs) (IC50 < 0.02 μM for Abl, Src, VEGFR-2 and PDGFR) and PI 3-K family kinases (IC50 < 0.06 μM for p110α, DNA-PK and mTOR).
A10903

Telatinib (BAY 57-9352)

VEGFR-2 inhibitor
Telatinib (BAY 57-9352) is an orally available, small-molecule inhibitor of vascular endothelial growth factor receptors 2 and 3 (VEGFR-2/-3) and platelet-derived growth factor receptor β tyrosine kinases.
A10468 SALE

Imatinib Mesylate

Bcr-Abl inhibitor
Imatinib mesylate, a selective tyrosine kinase inhibitor, induced a sustained objective response in treating gastrointestinal stromal tumors with the inhibition of the KIT signal-transduction pathway.
A10025 SALE

Linifanib (ABT-869)

VEGFR/PDGFR inhibitor
Linifanib (ABT-869) is a structurally novel, potent inhibitor of RTK, VEGF and PDGF with IC50 of 0.2, 2, 4, and 7 nM for human endothelial cells, PDGFR-β, KDR, and CSF-1R, respectively.
A11052 SALE

Crenolanib (CP-868596)

PDGFR Inhibitor
Crenolanib (CP-868596) is an orally bioavailable, selective small molecule inhibitor of the PDGFR tyrosine kinase, inhibiting both PDGFRA and PDGFRB at picomolar concentrations.
A16258

Flumatinib

multi-kinase inhibitor
Flumatinib is a multi-kinase inhibitor with IC50 Values of 1.2 nM, 307.6 nM and 2662 nM for c-Abl, PDGFRbeta and c-Kit respectively.

40 Item(s)

per page

Set Descending Direction